This trial is active, not recruiting.

Conditions aortic stenosis, aortic insufficiency
Treatment freedom solo stentless heart valve
Phase phase 3
Sponsor Sorin Group USA, Inc.
Start date December 2010
End date June 2014
Trial size 200 participants
Trial identifier NCT01115907, G100014


The purpose of this clinical investigation is to demonstrate the safety and effectiveness of the Freedom SOLO heart valve.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Appropriate subjects will receive the Freedom SOLO stentless valve implant as a replacement for a diseased or damaged native or prosthetic aortic valve.
freedom solo stentless heart valve
Freedom SOLO Stentless Heart Valve

Primary Outcomes

Safety will be determined by incidence rate of adverse events
time frame: 1 year

Secondary Outcomes

Efficacy will be determined by hemodynamics
time frame: 1 year
Effectiveness will be determined by NYHA Classification comparisons
time frame: 1 year

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - The subject is male or female 18 years old or older. - The subject or subject's legal representative is willing to sign the informed consent. - The subject which preoperative evaluation indicated the need for native or prosthetic aortic valve replacement. - Any subject amenable to aortic valve replacement with biological prosthesis should be enrolled in the study, even in conjunction with valve repair, coronary artery bypass grafting and other procedures. - The subject is located in a geographic location that will enable the subject to return to the study site for all follow-up examinations (i.e. geographically stable). - Subject will be available to the investigator(s) for postoperative follow-up beyond one year. Exclusion Criteria: - The subject has preexisting valve prosthesis in the mitral, pulmonary or tricuspid position. - The subject requires a double or multiple valve replacement (a valve repair is not considered an exclusion criterion). - The subject has a previously implanted SOLO valve, within the clinical study, that requires replacement. - The subject has active endocarditis or myocarditis. - The subject is or will be participating in a concomitant research study of an investigational product. - The subject is a minor, drug abuser, alcohol abuser, prison inmate, institutionalized, or is unable to give informed consent. - The subject has a major or progressive non-cardiac disease that, in the investigator's experience, results in a life expectancy of less than 1 year, or the implant of the device produces an unacceptable increased risk to the subject. - The subject is pregnant, planning to become pregnant or lactating. - The subject has a congenital bicuspid aortic valve. - The subject is known to be noncompliant or is unlikely to complete the study. - The subject is undergoing renal dialysis for chronic renal failure or has been diagnosed with hyperparathyroidism. - The subject has had an acute preoperative neurological deficit, myocardial infarction, or cardiac event that has not returned to baseline or stabilized ≥30 days prior to the planned valve implant surgery. - The subject has extensive calcification of the aortic root where removal of the calcified tissue cannot be achieved. - The subject has a significantly dilated aortic root that is not surgically corrected. - The subject requires replacement of the aortic root / full root procedure.

Additional Information

Official title Clinical Investigation of the Freedom SOLO Stentless Heart Valve in North America
Principal investigator Eric Roselli, M.D.
Description The SOLO clinical investigation is a prospective, non-randomized, multicenter trial of the SOLO Freedom heart valve implanted in patients requiring aortic valve replacement.
Trial information was received from ClinicalTrials.gov and was last updated in December 2013.
Information provided to ClinicalTrials.gov by Sorin Group USA, Inc..